

Documented results. Supported by science.

Vasomedical, Inc. provides superior medical products and services that address unmet clinical needs in the management of patients with heart disease.

The company's core technology, EECP® therapy, provides healthcare professionals with a noninvasive therapy for patients suffering from cardiovascular diseases. EECP® therapy improves patients' health and helps them lead more active and productive lives.

Over the Counter Bulletin Board (OTC)	VASO.OB
Recent Close (05/11/07)	\$0.075
52-week Trading Range	\$0.05– \$0.22
Market Cap. (05/11/07)	\$4.89 million
Shares Outstanding	65.20 million
Loss per Share (MRQ)	(\$0.01)
Fiscal Year End	May 31

EECP® THERAPY: NONINVASIVE THERAPY FOR ISCHEMIC HEART DISEASE

EECP® therapy is a noninvasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs, decreases the heart's workload and need for oxygen. It also improves function of the endothelium, the inner lining of blood vessels throughout the body, dilating arteries and reduces resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve the quality of life for thousands of patients worldwide.

EECP® THERAPY: BENEFITS FOR ALL STAKEHOLDERS

Stakeholder	EECP® THERAPY ADVANTAGE
Physicians	Ability to offer a complete treatment regimen for angina and heart failure Incremental source of revenue
Patients	Noninvasive treatment alternative for ischemic heart disease Clinically proven to reduce symptoms, increase activity, improve quality of life
Payers	A more cost effective alternate to costly, high-risk invasive procedures.

CMS established a national Medicare reimbursement policy for EECP® therapy in the treatment of patients with angina refractory in 1999.

Extensive third-party coverage policies have been established on an individual provider basis. Currently, there are over 300 third-party payers covering EECP® treatment.

INVESTMENT CONSIDERATIONS

- **EECP® systems are cleared to market by the Federal Food and Drug Administration for treating the following four cardiovascular conditions: angina, congestive heart failure, cardiogenic shock and acute myocardial infarction. Currently Vasomedical is marketing for angina and heart failure.**
- **Vasomedical has approximately two-thirds of EECP® therapy patients covered by Medicare.**
- **Vasomedical has approximately three-quarters market share, with over 1,000 EECP® therapy systems installed worldwide.**
- **Opportunity to grow the market for EECP® therapy and further increase sales.**
- **Management and sales team focused on delivering tangible results. Continuous growth of clinical evidence has provided targeted growth strategy with long-term goal of achieving broad-based clinical acceptance of EECP® therapy.**

MANAGEMENT TEAM

John C. K. Hui, Ph.D.

President and Chief Executive Officer, Director
Senior VP, Chief Technology Officer

Tricia Efstathiou, CPA

Chief Financial Officer

Harold Kaefer

VP, Engineering and Manufacturing

Larry Liebman

VP, Sales

BOARD OF DIRECTORS

Abraham E. Cohen

Chairman

John C. K. Hui, Ph.D

Tricia Efstathiou, CPA

Photios T. Paulson

Martin Zeiger

Simon Srybnik

Jun Ma, Ph.D

Ben Movaseghi, CPA

Derek Enlander, MD

GROWTH STRATEGY

- **Market EECP® therapy for CHF under existing national angina Medicare policy**
- **Obtain national Medicare and third-party payer coverage for CHF beyond patients covered under current policies**
- **Increase penetration of core U.S. angina market**
- **Pursue additional managed care relationships**
- **Expand revenue streams from service, education & consumables**

CORPORATE HEADQUARTERS

Vasomedical, Inc.

180 Linden Avenue

Westbury, NY 11590

Phone: (516) 997-4600

Fax: (516) 997-2299

www.vasomedical.com

www.eecp.com

www.naturalbypass.com

INVESTOR RELATIONS

Email: investorrelations@vasomedical.com



Documented results. Supported by science.

This corporate profile may contain forward-looking statements that involve risks and uncertainties. When used herein, words such as "anticipates," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and the information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the risk factors reported from time to time in the Company's SEC reports, including the ability of the Company to continue as a going concern. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.